The U.S. Food and Drug Administration has approved GSK plc’s HIBsago (bepirovirsen) injectable, used with existing antiviral therapy, for certain adults with chronic hepatitis B without cirrhosis. HIBsago is the first antisense oligonucleotide approved by the FDA to treat chronic hepatitis B. Eligible patients must have received at least six months of hepatitis B virus treatment, with HBV suppressed in the blood and HBsAg levels of no more than 3,000 IU/mL.
Source:FDA · Read original
Leave a Reply